Approximately 70% of human immunodeficiency virus (H1V)-1-infected pregnant women do not transmit HIV to their offsprings. The identification of factors involved in maternalchild transmission of HIV is important for the design and implementation of therapeutic and prevention strategies. Recently we have developed a modified peripheral mononuclear cell (PBMC) culture system for in vitro antibody production (IVAP) by which we can distinguish serum-derived cytophilic anti-HIV-1 antibody from de novo synthesized antibody. In this study, we analyzed the presence of antibodies directed to HIV-1 gp160, gp120, gp41, and V3 loop synthetic peptides (C51, C53, and C57 from MN and IIIB strains) utilizing the grid-blot method in PBMC cultures of 52 mother-child pairs. Among the mothers (39 nontransmitters and 13 transmitters), presence of serum-derived cytophilic antibodies or de novo synthesized HIV V3 loop peptide-specific antibodies did not correlate with vertical transmission. However, PBMC-associated, cytophilic antibodies of maternal origin reactive with C51, C53, and C57 from MN and IIIB strains were identified in cultures of uninfected infants, but not in infected infants. These observations suggest that cytophilic antibodies of maternal origin directed to HIV-1 V3 loop peptides which are 
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origin on infant PBMC may play a role in preventing trans-slotted portion of the acrylic plate of a SURF-BLOT apparatus mission of HIV.
(Idea Scientific Co., Minneapolis, MN). The foam pad followed by the metal plate of the apparatus were then stacked METHODS against the back of the nitrocellulose :sheet and the apparatus Study group. This study group consists of 52 pairs of HIV-1-infected mothers and their offspring. The infants were clinically monitored for periods of >18 mo of age and were determined as being infected or not infected according to the Communicable Disease Center criteria for HIV infection (22) . Culture supernatants from PBMC were collected in infants at age 5 3 mo, the mean age at time of sample collecting from HIV-infected infants was 1.45 t 0.65 mo (n = 13) and that of HIV-uninfected infants, 1.56 1 0.73 mo (n = 39). From the mothers, the blood samples were obtained at the same time as the infants. Based on their children's outcome, the mothers were divided into nontransmitting and transmitting groups. A retrospective analyses of antibody determination was performed in culture supernatants as described below.
PBMC culture procedure. PBMC were separated by Ficollhypaque density gradient centrifugation on Lymphoprep (Nucomed, Oslo, Norway) as previously described (20) . The cells were washed three times in Hanks' balanced salt solution and resuspended at a concentration of 1 X 1 0~/ m l in RPMI 1640 supplemented with 10% FCS, penicillin, and streptomycin. PBMC were then cultured for 1 h at 37"C, supernatants collected and designated as "1-h supernatants" (containing serum-derived cytophilic antibodies). After washing the PBMC again with PBS, cells were resuspended in RPMI with 10% FCS and cultured for additional 7 d; supernatants were collected and designated as "7-d supernatants" (containing antibodies synthesized de novo). The supernatants were stored at -20°C until assayed for presence of HIV antibodies by grid-blot and ELISA.
HZV-I envelope glycoproteins and synthetic peptides of V3 loop. HIV-1 envelope glycoproteins gp160 and gp120 were purified from supernatants of HIV-1,,,-infected clone of Hut 78 cells as described previously (23) . Immunodominant peptide from gp41 (JB4 IIIB) and peptides of V3 loop from HIV-1 MN and IIIB strains (C51, C53, C57) were kindly provided by Dr. Paolo Rossi, and the sequences are shown in Table 1 . p121 represents a segment of gp41, consisting of 80 amino acids from 566 to 645 (Repligen Corp., Cambridge, MA).
Grid-blot procedure for antibody determination. The gridblot procedure was carried out as described previously (21) . Briefly, a wet sheet of nitrocellulose paper previously soaked in Tris buffered saline (TBS) for 20 min was positioned on the min on a plateform shaker. The channels were washed twice with TBS and the apparatus disassembled. The antibody screening was performed by first blocking the nitrocellulose sheet in Blotto (2% non-fat milk in TBS) for 60 min followed by assembly of the sheet in the SURF-BLOT apparatus as described above, except that the sheet was rotated 90" clockwise so that the channels were now oriented at right angles to the row of absorbed specific antibody on the nitrocellulose sheet. One hundred microliters of supernatant were added to each channel. The SURF-BLOT was incubated for 60 min as before, the channels were washed, and the device was disassembled. To visualize the anti-V3 loop IgG, the nitrocellulose sheets were incubated with alkaline phosphatase-conjugated goat-anti-human IgG (1:1000 dilution) for 60 min, washed in TBS, and visualized with the 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium. ELISA for detecting anti-HZV-1 gp160 IgG in supernatants. The method followed was essentially as described previously (20) . Briefly, culture supernatants were added in duplicate wells to the plates coated with HIV-1 gp160 and incubated for 1 h at 37°C. Bound anti-gpl60 IgG was detected by alkaline phosphatase-conjugated goat F(abr), anti-human IgG antibody (Tago Inc., Burlingame, CA). The OD of absorbance was measured at 405 nm on a microplate reader (Coulter Electronics Inc., Hialeah, FL) and analyzed on the Softmax ELISA program (Molecular Devices, Menlo Park, CA).
Statistical analysis. Comparisons of the OD value from HIV-1 gp160 ELISA were made between the transmitting and nontransmitting groups of mothers and infected and uninfected infants. The data were analyzed using the unpaired t test. For determination of differences in reactivity to HIV-1 V3 loop peptides between the groups, Fisher's exact test was performed.
RESULTS
Sensitivity of grid-blot.
The grid-blot assay can be adapted to screen antibody reactivities to a wide range of peptides or antigens for study of humoral immunity in serum andlor culture supernatants (21) . In this study, the sensitivity was assessed by HIV-1 envelope gp41 and anti-gp41 MAb (p121 and MAb 2A2, respectively): the limitation of detecting antibody was 1.56 ng/ml when PI21 antigen (3 pg/ml) was loaded on nitrocellulose. One hundred percent sensitivity was obtained when applying this assay to detect anti-HIV IgG in IVAP supernatants from HIV+ individuals (24) . Typical results of grid-blot for detecting IgG antibodies against HIV-1 gp160, gp120, JB4 IIIB, and peptides from V3 loop in IVAP supernatants from maternal-child pairs are shown in Figure 1 . Presence of anti-V3 loop antibodies in PBMC supernatants from mothers did not correlate with vertical transmission. We have demonstrated that the revised culture procedure of PBMC for IVAP could distinguish between serum-derived cytophilic anti-HIV antibodies which adhere to the surface of PBMC and are released into the 1-h supernatants from those synthesized de novo and are secreted into the 7-d supernatants (20) . When the 1-h supernatants from PBMC of transmitting and nontransmitting mothers are analyzed for antibodies to HIV-1 by ELISA and grid-blot, the results did not show any significant difference between the two groups; the OD values for anti-HIV-1 gp160 IgG ELISA were 1.32 i 0.73 in nontransmitters and 1.35 f-0.63 in transmitters (Fig. 2) . Reactivity to HIV-1 gp160, gp120, gp41, and V3 loop peptides C51, C53, and C57 from MN and IIIB strains in the two groups are shown in Table 2 , and no difference was noted between them. The 7-d supernatants which contain anti-HIV antibodies produced by PBMC in vitvo and represent a humoral immune response to HIV infection were analyzed by ELISA and gridblot. No significant differences were observed between the nontransmitter and transmitter groups; the OD values from anti-HIV-1 gp160 IgG ELISA were 0.37 t 0.28 and 0.59 + 0.54, respectively (t = 1.91 p > 0.05) (Fig. 2) . Reactivities to HIV-1 gp160, gp120, gp41, and V3 loop peptides C51, C53, and C57 from MN and IXIB strains from the 7-d supernatants were also not different in the two groups ( Table 3) .
Correlation of maternally serum-derived cytophilic anti-V3 loop antibodies in PBMC supernatants of infants with vertical transmission. We analyzed anti-HIV gp160 IgG and antibodies against HIV V3 loop peptides in 1-h culture supernatants of PBMC from infants. Cytophilic antibodies of maternal origin have been shown previously to be released in these supernatants (20) . Results show that antibodies against HIV-1 V3 loop peptides (C51, C53, and C57 from MN and IIIB strains) could be detected only in noninfected infants (Table 4) . Of 39 seroreverters, 17 had antibodies to 1 or more V3 loop peptides. In their 1-h supernatants, antibody to C53 MN was the most frequent and was detectable in 1-h supernatants of 14 infants (p < 0.05). None of the infected infants had detectable V3 loop peptide antibodies in their 1-h supernatants. The mean OD of anti-HIV gp160 in 7-d supernatants which represent de novo antibody production was 0.04 + 0.02 in noninfected infants, and 0.132 2 0.277 in infected infants (t = 2.13, p < 0.05) (Fig. 3) . Anti-HIV gp160 IgG in the 1-h supernatants was not different between noninfected and infected infants, the mean OD being 0.51 & 0.44 and 0.52 2 0.57, respectively (Fig. 3) . These results were also confirmed in reactivity to HIV gp160 by grid-blot.
DISCUSSION
Transplacental transfer of maternal antibodies to infants is known to be an important component of protective immunity against a variety of infectious agents. However, the role of anti-HIV antibodies in vertical transmission of HIV is unclear. In this study, we have demonstrated that maternally derived HIV V3 loop directed antibodies adhering to infant PBMC, when present, were associated with a lack of infection in the infants.
We have previously observed (20) that 1-h supernatants from cultured PBMC contain serum-derived cytophilic antibodies which are released from the surface of the PBMC. If these cells were washed and recultured, then no HIVspecific antibody was detected in 24-h supernatants either in infected or uninfected infants; HIV-specific antibody was detectable in 7-d culture supernatants only from HIVinfected infants, representing de novo antibody secretion. HIV-1-specific antibodies detectable in 1-h supernatants of PBMC from uninfected infants were demonstrated to be maternal in origin. We investigated the relationship of maternal HIV V3 loop-specific antibodies with vertical The V3 loop peptide-specific antibodies in 1-h PBMC supernatants from mothers which contain serum-derived cytophilic antibodies were detected by grid-blot; 39 mothers had HIV-uninfected infants (nontransmitters), 13 mothers had HIV-infected infants (transmitters). Numbers in parentheses indicate percentages showing positive results. (23) 2113 (16) 2113 (16) 2113 (16) 2113 (16) 2/13 (16) The V3 loop peptide-specific antibodies in 7-d PBMC supernatants from mothers which contain de novo synthesized antibodies were detected by grid-blot; 39 mothers had HIV-uninfected infants (nontransmitters), 13 
mothers had HIV-infected infants (transmitters). Numbers in parentheses indicate percentages showing positive results
Table 4. Anti-V3 loop cytophilic antibodies of maternal origin in PBMC cultures of infants correlated with lack of HIV transmission
No. of supernatants reactive by grid-blot to: The V3 loop peptide specific antibodies in I-h PBMC supernatants from infants (<3 mo) which contain cytophilic antibodies of maternal origin were determincd by grid-blot; 39 infants seroreverted (not infected), 13 infants were HIV-infected. Numbers in parentheses indicate percentages showing positive results. * A significant difference was noted between not infected and infected infants for antiLC53 MN peptide antibody, p < 0.05. transmission in PBMC culture supernatants from motherinfant pairs. The grid-blot method was selected because of the ease with which screening for antibodies to different HIV-1 envelope gp and V3 peptides could be performed using 100 p1 of the culture supernatant.
In the 52 mothers studied (39 nontransmitter and 13 transmitter), presence of serum-derived cytophilic antibodics or cle novo synthesized HIV V3 antibodies in maternal PBMC cultures did not correlate with vertical transmission. However, in the PBMC of their infants, serum-derived maternal cytophilic antibodies directed to C51, C53, and C57 from MN and IIIB strains, most prominently C53 MN antibody could be eluted only from cells of uninfected infants, but not of infected infants. These observations suggest that cytophilic antibodies of maternal origin directed to HIV-1 V3 loop peptides are transferred selectively and get bound to infant cells. Whether or not such cytophilic binding of antibody occurs may depend on as yet undetermined characteristics of antibodies, e.6 antibody affinity or the presence of viral replication in the infected children which might have resulted in a decrease in HIVspecific antibody available for binding to Fc-bearing cells. The protective mechanism is also speculative; presence of antibody on target cells could, for instance, protect the cells from virus entry.
The rcactivity to HIV gp160, gp120, gp41 (JB4IIIB), and V3 loop peptides in 1-h supernatants from mothers in both groups was detected. Although the trend for a higher reactivity to C53 MN in 1-h supernatants was observed in nontransmitting mothers, these results provide evidence that presence of HIV V3 loop-specific antibody in the mothers does not correlate with lower vertical transmission. This finding is consistent with recent reports indicating that HIV V3-specific antibody in mothers did not reveal a correlation with prevention from HIV infection in their offsprings (14, (16) (17) (18) (19) . Additionally, in the present study, humoral immunity to HIV infection in mothers as evaluated by de novo antibody synthesis was also not related with vcrtical transmission, since the levels were equivalent in transmitting and nontransmitting mothers.
Among previous published reports about maternal HIV V3-specific antibodies with vertical transmission, three studies screened reactivity to V3 loop peptides in serum from infants by ELISA: two studies found t h a t maternal HIV V3 specific antibodies in serum from infants correlated with low vertical transmission (12, 13) , whereas one did not observe a significant difference between infected and uninfected infants (19) . In our study, maternally derived cytophilic HIV-1 V3 specific antibodies could only be detected in some and not all uninfected infants which suggests that cytophilic antibodies specific for different V3 loop sequence might be present on infant PBMC and/or that other factors are of importance in protection from vertical transmission. Factors which have been shown to play a role in transmission of infection from mother to infants include maternal CD4 count, virus burden in the mothers (25) and HIV-specific immunity in the fetus (26) . Factors affecting timing of transmission may have an overriding influence on protective role of humoral immunity, because placental transfer occurs only late during the third trimester and a fraction of infants does appear to get infected early in gestation (27).
In our study, cross-reactivity to V3 loop peptides from MN and IIIB strains was observed, although the predominant strain in the present study was MN. The cross-reactivity is a common phenomenon among HIV-1 V3-specific antibodies, and the predominant reactivity to the MN strain is consistent with the high prevalence of HlV MN-related viruses in the United States (28, 29) .
Our results suggest that, although the "presence" of maternal HIV V3-specific antibodies in mothers may of itself not correlate with vertical transmission, their adherence to infant PBMC may play a role in prevention of HIV vertical transmission.
